Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Hepatology. 2014 Jan 30;59(3):898–910. doi: 10.1002/hep.26592

Fig. 5. Treatment with IL-1 receptor antagonist partially attenuates liver pathology in Nlrp3 CreZ mice.

Fig. 5

Nlrp3 CreZ mutant mice and WT were treated with 300 mg/kg IL-1 receptor antagonist (anakinra) or saline from day 2 to 13. Liver histology of anakinra treated mutants showed a marked decrease in liver inflammation and TUNEL positive cells, whereas collagen deposition assessed by sirius red staining was unaffected (A). Correspondingly, mRNA levels of TNF-α and pro-Casp1 were significantly decreased and mRNA levels of pro-IL-1β showed a trend towards lower levels in anakinra treated mutants in comparison to saline injected mutants (B). Notably, markers of hepatic stellate cell activation, CTGF and TIMP1, were not significantly altered in anakinra treated mice (C); (n≥ 3 for each group).